[
  {
    "ts": "2025-11-25T08:11:23+00:00",
    "headline": "Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors?",
    "summary": "Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as a neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer in patients ineligible for cisplatin-containing chemotherapy, following strong results from the Phase 3 EV-303 trial. This milestone extends Pfizer’s reach in oncology by offering a much-needed treatment option for patients with limited chemotherapy alternatives and underscores ongoing progress in...",
    "url": "https://finance.yahoo.com/news/fda-approval-padcev-keytruda-combo-081123602.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "bc248386-7755-3e12-8e0c-a90745023b0b",
      "content": {
        "id": "bc248386-7755-3e12-8e0c-a90745023b0b",
        "contentType": "STORY",
        "title": "Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors?",
        "description": "",
        "summary": "Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as a neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer in patients ineligible for cisplatin-containing chemotherapy, following strong results from the Phase 3 EV-303 trial. This milestone extends Pfizer’s reach in oncology by offering a much-needed treatment option for patients with limited chemotherapy alternatives and underscores ongoing progress in...",
        "pubDate": "2025-11-25T08:11:23Z",
        "displayTime": "2025-11-25T08:11:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-padcev-keytruda-combo-081123602.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-padcev-keytruda-combo-081123602.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-25T11:24:00+00:00",
    "headline": "Is This the Best Value Stock to Buy While Markets Are Volatile?",
    "summary": "This big pharma stock should be even more appealing to investors amid market turbulence.",
    "url": "https://www.fool.com/investing/2025/11/25/is-this-the-best-value-stock-to-buy-while-markets/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "297b7221-1a4b-3886-98b9-aca1c99ecdda",
      "content": {
        "id": "297b7221-1a4b-3886-98b9-aca1c99ecdda",
        "contentType": "STORY",
        "title": "Is This the Best Value Stock to Buy While Markets Are Volatile?",
        "description": "",
        "summary": "This big pharma stock should be even more appealing to investors amid market turbulence.",
        "pubDate": "2025-11-25T11:24:00Z",
        "displayTime": "2025-11-25T11:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/2ddefc90b4798f5aaa8d6d65071e9689",
          "originalWidth": 1024,
          "originalHeight": 652,
          "caption": "Pfizer logo on glass.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BG7eAkOIM.GOVSLa5GewMw--~B/aD02NTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/2ddefc90b4798f5aaa8d6d65071e9689.cf.webp",
              "width": 1024,
              "height": 652,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/svZ0P7PmKqwoZSVJXlBClQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/2ddefc90b4798f5aaa8d6d65071e9689.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/25/is-this-the-best-value-stock-to-buy-while-markets/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/best-value-stock-buy-while-112400261.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-25T12:24:00+00:00",
    "headline": "J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?",
    "summary": "J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.",
    "url": "https://finance.yahoo.com/news/j-j-around-17-3-122400598.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "8392a715-958e-3f0a-b30d-1fda5fff8259",
      "content": {
        "id": "8392a715-958e-3f0a-b30d-1fda5fff8259",
        "contentType": "STORY",
        "title": "J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?",
        "description": "",
        "summary": "J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.",
        "pubDate": "2025-11-25T12:24:00Z",
        "displayTime": "2025-11-25T12:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WtA490SSyXq.BB5XEEYFSg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BdQSUWaJAMCKg7gp75c9jQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-around-17-3-122400598.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-around-17-3-122400598.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-25T08:00:00+00:00",
    "headline": "4 takeaways from pharma’s manufacturing boom",
    "summary": "As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.",
    "url": "https://www.pharmavoice.com/news/pharma-manufacturing-boom-takeaways/806347/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "7eddfa3d-98b0-310a-9cbc-1410d8520d34",
      "content": {
        "id": "7eddfa3d-98b0-310a-9cbc-1410d8520d34",
        "contentType": "STORY",
        "title": "4 takeaways from pharma’s manufacturing boom",
        "description": "",
        "summary": "As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.",
        "pubDate": "2025-11-25T08:00:00Z",
        "displayTime": "2025-11-25T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/55be0bf0554fdae9f49f7f23956f3bc7",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u9czpu1ZeOo83B1Iq3OOWQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/55be0bf0554fdae9f49f7f23956f3bc7.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gTwKjxJU4WV1UEhIzppTlA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/55be0bf0554fdae9f49f7f23956f3bc7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/pharma-manufacturing-boom-takeaways/806347/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/4-takeaways-pharma-manufacturing-boom-080000234.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-25T14:47:00+00:00",
    "headline": "Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial",
    "summary": "The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-says-new-obesity-drug-helps-patients-lose-weight-in-mid-stage-trial-ce87171f?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "6baa046b-8b30-3a62-83e7-1ff37bdfb168",
      "content": {
        "id": "6baa046b-8b30-3a62-83e7-1ff37bdfb168",
        "contentType": "STORY",
        "title": "Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial",
        "description": "",
        "summary": "The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.",
        "pubDate": "2025-11-25T14:47:00Z",
        "displayTime": "2025-11-25T14:47:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/6baa046b-8b30-3a62-83e7-1ff37bdfb168/novo-nordisk-drug-helps.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6a7c78c25f6e6db2b81c83134ab9aad5",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LLMQ.FBU5_TZC1NTldxM7Q--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6a7c78c25f6e6db2b81c83134ab9aad5.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6NHuFfgdqE3ajmE8GfufTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6a7c78c25f6e6db2b81c83134ab9aad5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-says-new-obesity-drug-helps-patients-lose-weight-in-mid-stage-trial-ce87171f?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-25T17:28:00+00:00",
    "headline": "FDA Decision Opens Bigger Market for Novartis’s Blockbuster Gene Therapy",
    "summary": "Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.",
    "url": "https://www.barrons.com/articles/novartis-sma-zolgensma-fda-stock-9b5c2717?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f6009a60-1eb3-310f-8a25-3cd78b7e3569",
      "content": {
        "id": "f6009a60-1eb3-310f-8a25-3cd78b7e3569",
        "contentType": "STORY",
        "title": "FDA Decision Opens Bigger Market for Novartis’s Blockbuster Gene Therapy",
        "description": "",
        "summary": "Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.",
        "pubDate": "2025-11-25T17:28:00Z",
        "displayTime": "2025-11-25T17:28:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f6009a60-1eb3-310f-8a25-3cd78b7e3569/fda-decision-opens-bigger.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/a986a7c04ba3dd800a0b8b27e30605bb",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qKMNtTYvZyFg8_qLfaLGiw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/a986a7c04ba3dd800a0b8b27e30605bb.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RNCnqCDX7AeKHBU3.TnFlA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/a986a7c04ba3dd800a0b8b27e30605bb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novartis-sma-zolgensma-fda-stock-9b5c2717?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-25T11:30:00+00:00",
    "headline": "Bayer Resurrects Scrapped Blood-Thinning Drug as Breakthrough Stroke Treatment",
    "summary": "The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.",
    "url": "https://www.thedailyupside.com/industries/healthcare/bayer-resurrects-scrapped-blood-thinning-drug-as-breakthrough-stroke-treatment/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "96d76b9f-aa4b-32bc-9911-9f2034cf7070",
      "content": {
        "id": "96d76b9f-aa4b-32bc-9911-9f2034cf7070",
        "contentType": "STORY",
        "title": "Bayer Resurrects Scrapped Blood-Thinning Drug as Breakthrough Stroke Treatment",
        "description": "",
        "summary": "The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.",
        "pubDate": "2025-11-25T11:30:00Z",
        "displayTime": "2025-11-25T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/6a39d535f2e4ef9e6c7effc2d30340df",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Photo of a Bayer AG office building.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oL0ICHfGKa95jbg4R1O0yQ--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/6a39d535f2e4ef9e6c7effc2d30340df.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6BKm02o65HZcR_4Zo4I8lQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/6a39d535f2e4ef9e6c7effc2d30340df.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/industries/healthcare/bayer-resurrects-scrapped-blood-thinning-drug-as-breakthrough-stroke-treatment/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bayer-resurrects-scrapped-blood-thinning-113000634.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]